The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice.

The protective efficacy of the influenza matrix protein epitope 58-66 (called M1), recognized in the context of human HLA-A2 molecules, was evaluated in a HLA-A2/K(b) transgenic mouse model of lethal influenza infection. Repeated subcutaneous immunizations with M1 increased the percentage of survival. This effect was mediated by T cells since protection was abolished following in vivo depletion of all T lymphocytes, CD8(+), or CD4(+) T cells. The survival correlated with the detection of memory CD8(+) splenocytes able to proliferate in vitro upon stimulation with M1 and to bind M1-loaded HLA-A2 dimers, as well as with M1-specific T cells in the lungs, which were directly cytotoxic to influenza-infected cells following influenza challenge. These results demonstrated for the first time that HLA-A2-restricted cytotoxic T cells specific for the major immunodominant influenza matrix epitope are protective against the infection. They encourage further in vivo evaluation of T cell epitopes recognized in the context of human MHC molecules.

[1]  D. Stott,et al.  Influenza Vaccination of Health Care Workers in Long-Term-Care Hospitals Reduces the Mortality of Elderly Patients , 1997, The Journal of infectious diseases.

[2]  V. Engelhard,et al.  Lipopeptide‐based melanoma cancer vaccine induced a strong MART‐27‐35‐cytotoxic T lymphocyte response in a preclinal study , 2002, International journal of cancer.

[3]  P. Robbins,et al.  A broad cytotoxic T lymphocyte response to influenza type B virus presented by multiple HLA molecules. , 1997, International immunology.

[4]  I. Frazer,et al.  The number of long‐lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation , 2002, European journal of immunology.

[5]  A. McMichael,et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.

[6]  D. Valmori,et al.  Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. , 1992, Journal of immunology.

[7]  R. Khanna,et al.  Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design. , 2001, Vaccine.

[8]  D. Xu,et al.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes. , 2001, World journal of gastroenterology.

[9]  E. D. Kilbourne,et al.  Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. McFarland,et al.  The Immune Response to Viruses , 1989 .

[11]  W. Dupont,et al.  A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. , 1994, The Journal of infectious diseases.

[12]  B. Askonas,et al.  Rapid recovery of lung histology correlates with clearance of influenza virus by specific CD8+ cytotoxic T cells. , 1989, Immunology.

[13]  A. Falsey,et al.  Respiratory syncytial virus and influenza A infections in the hospitalized elderly. , 1995, The Journal of infectious diseases.

[14]  A. Vitiello,et al.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex , 1991, The Journal of experimental medicine.

[15]  Karen McAulay,et al.  Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial , 2000, The Lancet.

[16]  J. Guillet,et al.  Generation of Melan‐A/MART‐1‐specific CD8+ cytotoxic T lymphocytes from human naive precursors: Helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro , 1997, International journal of cancer.

[17]  J. Bonnefoy,et al.  CD4+ T-Cell-Mediated Antiviral Protection of the Upper Respiratory Tract in BALB/c Mice following Parenteral Immunization with a Recombinant Respiratory Syncytial Virus G Protein Fragment , 2000, Journal of Virology.

[18]  John Cruz,et al.  Human Cytotoxic T-Lymphocyte Repertoire to Influenza A Viruses , 1998, Journal of Virology.

[19]  F. Ennis,et al.  Active immunization against virus infections due to antigenic drift by induction of crossreactive cytotoxic T lymphocytes , 1989, The Journal of experimental medicine.

[20]  M. Uhlén,et al.  Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. , 1997, Virology.

[21]  D. Okita,et al.  Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins. , 2000, The Journal of infectious diseases.

[22]  M. A. Saper,et al.  Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.

[23]  A. McMichael,et al.  Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2 , 1987, Nature.

[24]  S. Buus,et al.  Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes. , 1999, Vaccine.

[25]  T. Nguyen,et al.  Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. , 1999, Virology.

[26]  G. Parmiani,et al.  A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. , 1999, Cancer research.

[27]  P. Small.  Influenza: pathogenesis and host defense. , 1990, Hospital practice.

[28]  J. Bennink,et al.  Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. , 2000, International immunology.

[29]  J. Altman,et al.  In vivo proliferation of naïve and memory influenza-specific CD8(+) T cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Jung,et al.  Detection and Quantification of CD4+ T Cells with Specificity for a New Major Histocompatibility Complex Class II-Restricted Influenza A Virus Matrix Protein Epitope in Peripheral Blood of Influenza Patients , 2000, Journal of Virology.

[31]  Alessandro Sette,et al.  Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity1 , 2001, The Journal of Immunology.

[32]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[33]  L. BenMohamed,et al.  Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. , 2000, Human immunology.

[34]  P. Romero,et al.  Induction of a cytotoxic T cell response by co‐injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): Further enhancement by pre‐injection of IFA alone , 1994, European journal of immunology.

[35]  J. Altman,et al.  Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. , 1998, Immunity.

[36]  E. Julien,et al.  Stability and CTL activity of N-terminal glutamic acid containing peptides. , 2001, Journal of Peptide Research.

[37]  Wolfgang Weninger,et al.  Migratory Properties of Naive, Effector, and Memory Cd8+ T Cells , 2001, The Journal of experimental medicine.

[38]  R. Jaenisch,et al.  Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells , 1991, The Journal of experimental medicine.

[39]  P. Doherty,et al.  Contemporary Analysis of MHC-Related Immunodominance Hierarchies in the CD8+ T Cell Response to Influenza A Viruses1 , 2000, The Journal of Immunology.

[40]  R. Steinman,et al.  Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class I-restricted cytolytic lymphocytes upon adoptive transfer. , 2000, International immunology.

[41]  B. Moss,et al.  Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes , 1987, The Journal of experimental medicine.

[42]  Small Pa,et al.  Influenza: pathogenesis and host defense. , 1992 .

[43]  H. Sacks,et al.  The Efficacy of Influenza Vaccine in Elderly Persons , 1995, Annals of Internal Medicine.

[44]  T. Tumpey,et al.  Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. , 2001, Cellular immunology.

[45]  C. Bona,et al.  Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells. , 1998, Journal of immunology.

[46]  G. Air,et al.  Antigenic drift in type A influenza virus: peptide mapping and antigenic analysis of A/PR/8/34 (HON1) variants selected with monoclonal antibodies. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C Oseroff,et al.  Human memory CTL response specific for influenza A virus is broad and multispecific. , 2000, Human immunology.

[48]  F. Ennis,et al.  Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice. , 1981, Journal of immunology.

[49]  V. Engelhard,et al.  Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. , 1995, International immunology.

[50]  M. Bachmann,et al.  Influenza virus: a novel method to assess viral and neutralizing antibody titers in vitro. , 1999, Journal of immunological methods.

[51]  A. Cerwenka,et al.  Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. , 1999, Journal of immunology.

[52]  Alan D. Roberts,et al.  Activated Antigen-Specific CD8+ T Cells Persist in the Lungs Following Recovery from Respiratory Virus Infections1 , 2001, The Journal of Immunology.

[53]  L. Sherman,et al.  Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. , 1992, Science.

[54]  A. Cerwenka,et al.  Migration Kinetics and Final Destination of  Type 1 and Type 2 CD8 Effector Cells Predict Protection against Pulmonary Virus Infection , 1999, The Journal of experimental medicine.

[55]  V. Engelhard,et al.  Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein. , 1991, Journal of immunology.